prIME Masterclass in Neuroendocrine Tumors

prIME Masterclass in Neuroendocrine Tumors

A Multidisciplinary Interactive Workshop

Not a member of My prIME? Join now for instant access.

Meeting Overview

Engage with experts in the field of neuroendocrine tumors (NETs) by joining this highly interactive 1.5-day live meeting. Our experts will provide a comprehensive update on the management of NETs, focusing on recent developments in imaging and therapeutic options by using the following strategies:

  • Didactic presentations
  • Interactive workshops
  • Case-based presentations and clinical management discussions
  • “Beat the Experts” NETs quiz
  • Q & A sessions

Date and Location

Friday & Saturday,
29 – 30 November 2019

Room: Ballroom
Hilton Budapest
Hess András tér 1-3
Budapest, Hungary

Date/Time

Date/Time

29 – 30 November 2019

Location

Location

Budapest, Hungary

Friday, 29 November—Day 1

10.30 Registration
12.00 Lunch
13.00 Welcome and introduction

SESSION I: Biology, Pathology, and Prognosis

13.15 Pathology workshop
13.45 Intracellular targeting of NETs
14.15 Keynote lecture—Affordability of new cancer treatments: Can we do anything about spiraling costs?
14.45 Challenges in NET management: How does the expert do it?
14.45    Small bowel resection
15.05    Follow-up: How long and how best?
15.25    Metabolic complications of neuroendocrine neoplasia (NEN)
15.45    Screening and surveillance in multiple endocrine neoplasia type 1 (MEN 1)
16.05 Coffee break

SESSION II: Workshops

16.30 Peptide receptor radionucleotide therapy (PRRT)
16.55 Functional imaging for NETs
17.20 Interventional radiology
17.45 Genomics in clinical decision making for NET management
18.10 Evening break
20.00 Reception
20.15 Dinner

Saturday, 30 November—Day 2

08.00 Breakfast

SESSION III: Therapy and Patient Care

08.45 Keynote lecture—Immunotherapy: Can we apply to NETs?
09.15 Q & A
09.45 Literature review:  Basic science—what is new in 2019?
10.15 Literature review: Clinical—what is new in 2019?
10.45 Coffee break

SESSION IV: NET Fellows Forum

11.15 Pancreatic NETs
11.45 Rectal NETs
12.15 Pulmonary NETs
12.45 Lunch
13.45 “Beat the Experts” NETs quiz
14.00 Keynote Lecture—Clinical decision making: Discussing risk with your patient
14.30 Current knowledge and future perspectives on NET treatment
15.00 prIME Points™ and award ceremony
15.15 Afternoon coffee break and adjourn

Faculty

    Co-Chairs

  • Dermot O’Toole, MD, FRCPISt Vincent’s University Hospital
    St James's Hospital
    Trinity College Dublin
    Dublin, Ireland
  • Philippe Ruszniewski, MDParis University
    Beaujon Hospital
    Clichy, France
  • Faculty

  • Jaume Capdevila, MD, PhDVall d’Hebron University Hospital
    Barcelona, Spain
  • Justo Castaño, MS, PhDMaimonides Institute of Biomedical Investigation of Cordoba (IMIBIC)
    Cordoba, Spain
  • Lesley Fallowfield, FMedSci, Dphil, BScUniversity of Sussex
    Brighton, United Kingdom
  • Wouter de Herder, MD, PhDErasmus MC
    Rotterdam, the Netherlands
  • Reza Kianmanesh, MD, PhDR. Debré University Hospital
    Reims, France
  • Prakash Manoharan, MBChB, MRCP, FRCRThe Christie Neuroendocrine Centre of Excellence
    Manchester, United Kingdom
  • Marianne Pavel, MDUniversity Hospital Erlangen
    Erlangen, Germany
  • Maxime Ronot, MD, PhDBeaujon University Hospital
    Clichy, France
  • Jean-Yves Scoazec, MD, PhDGustave Roussy
    Villejuif, France
  • Chrissie Thirlwell, BSc, MD, PhD, FRCPUniversity College London
    The Royal Free Hospital
    London, United Kingdom
  • Eva Tiensuu Janson, MD, PhDUppsala University
    Uppsala, Sweden
  • Christos Toumpanakis, MD, PhD, FRCPThe Royal Free Hospital
    London, United Kingdom
  • Juan Valle, MD, ChB, MSc, FRCPThe Christie NHS Foundation Trust
    University of Manchester
    Manchester, United Kingdom

*Additional faculty to be confirmed

This educational activity is designed for European medical oncologists, endocrinologists, gastroenterologists, nuclear medicine specialists, and other healthcare providers involved and/or interested in the management of patients with NETs.

After successful completion of this educational activity, participants should be able to:

  • Describe the epidemiology, clinical characteristics, and natural history of NETs
  • Understand the cellular pathways of relevance in NETs and the role of molecular pathology in patient management
  • Select appropriate therapy from the increasing range of therapeutic options available for first and subsequent lines of treatment
  • Identify the potential for novel therapeutic strategies in the treatment of NETs

This educational activity is supported by Ipsen.

Independent Medical Education (IME)

This IME activity is organized by prIME, a Medscape Oncology Company. This activity provides content that is evidence-based, balanced, and free of commercial bias, with a primary objective to improve competence and performance of learners in order to improve patient care.

Provider

This activity is provided by prIME, a Medscape Oncology Company.

Sunshine Act/EFPIA

prIME, a Medscape Oncology Company complies with all Sunshine Act reporting requirements as outlined by CMS and applicable manufacturers and with EFPIA Disclosure Code reporting requirements.

Disclosures

Disclosure of Relevant Financial Relationships

prIME Oncology assesses the relevant financial relationships of its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.